Events & Ideas
Fields S, Henningfield J, Correa-Fernandez V, Davis D, de Dios M, Garcia-Romeu A, Heads A, Hood C, Hudzik T, Martinez S, Moreland A, Skinstad A, Wilkerson, Jr J. Presented at the American College of Neuropsychopharmacology 60th Annual Meeting, December 5–8, 2021.
Coker A, Yazar-Klosinski B, Emerson A, Doblin R, Coe M, Henningfield JA If MDMA is approved for therapeutic use by the FDA, then it must be removed from Schedule I and placed in the most appropriate schedule based in part on analysis of 8 factors listed in the CSA. Although further analyses will be considered… Read More
Gauvin D, Henningfield JE, Fant RV, Buchhalter AR, Ashworth J, Caron J, Pappagallo M, Bifari F, Folli F, Manfredi PL REL-1017 (esmethadone) is a novel NMDA channel blocker in development for major depressive disorder (MDD). REL-1017 has twenty-fold lower affinity than levomethadone at the mu-opioid receptor. According to a 2019 DEA statement, “The d-isomer lacks… Read More
Fields S, Henningfield J, Regan T, Correa-Fernandez V, de Dios M, Garcia-Romeu A, Heads A, Hood C, Hudzik T, Moreland A, Skinstad A Advancing equity, inclusion and diversity is vital to increase innovation and the excellence of science as well at its relevance to societal and public health needs. This survey was developed to support… Read More
Henningfield, J., Barr, M., Wang, D. and Huestis, M. American College of Neuropsychopharmacology, virtual meeting, Poster presented virtually, December 9, 2020.